Navigation Links
Actinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference
Date:2/6/2013

NEW YORK, Feb. 6, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTC BB: CTVN) a biopharmaceutical company that develops innovative alpha particle immunotherapeutics, is pleased to announce that Mr. Jack Talley , Actinium's President & CEO will be presenting at the 15th Annual BIO CEO & Investor Conference on Monday, February 11th at 10:15 AM EST.  Mr. Talley will provide an overview of the Company and its corporate activities. The logistics and webcast information are shown below.

Details Of The Event

Date: February 11, 2013

Time: 10:15 AM EST

Location: Park South, 4th Floor; Waldorf Astoria Hotel; New York, NY

Live and Archived Webcast link:

http://www.veracast.com/webcasts/bio/ceoinvestor2013/97107391.cfm

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a New York, New York based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 isotopes in association with monoclonal antibodies.  The Company also develops other radiopharmaceuticals for select applications.

For more information:
Visit our web site www.actiniumpharmaceuticals.com or contact:

Media: 
Dennis S. Dobson Jr., 203-258-0159

Jack Talley , CEO 
Actinium Pharmaceuticals Inc. 

Tel:  (646) 459-4201 

E-mail: actimaba@actiniumpharmaceuticals.com

Investors: 

Jeff Ramson  
CEO of ProActive Capital Group, LLC 

Tel:  (646) 863-6341 

E-mail: jramson@proactivecapitalgroup.com
www.proactivecapitalgroup.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals to Present at EMIT Targeted Radiotherapy Conference
2. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
3. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
4. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
5. Actinium Pharmaceuticals Announces New Round of Financing
6. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
7. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
8. Actinium Pharmaceuticals Stockholders Vote to Approve Fundraising and Public Listing
9. Actinium Pharmaceuticals Strengthens Management Team
10. Actinium Pharmaceuticals and Philogen S.p.A. Announce Collaboration for Alpha Therapy Based Antiangiogenesis Program
11. Actinium Pharmaceuticals Announces The Addition of The Fred Hutchinson Cancer Research Center To Actiniums Multicenter Clinical Trial For Patients With Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
(Date:6/23/2016)... June 23, 2016 Revolutionary technology ... Oticon , industry leaders in advanced audiology and ... Oticon Opn ™, the world,s first internet connected ... for IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... a number of ,world firsts,: , TwinLink™ ...
Breaking Medicine Technology:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... On ... as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle ... honor of the city’s history as home to some of the world’s leading providers ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
Breaking Medicine News(10 mins):